Safety and tolerability of intrathecal liposomal amphotericinB (AmBisome) for cryptococcal meningitis:a retrospective study in HIV-infected patients

摘要

Background:While mortality of HIV-related cryptococcal meningitis (CM) in developed countries is relatively low, in developing countries over half of patients die within 10 weeks. Current recommended therapies are often not suitable for resource-poor settings, and new shorter regimens are urgently needed. Intrathecal administration of liposomal amphotericin B (lAmB) has shown promising results in animal models. However, the safety and tolerability of intrathecal lAmB in humans are not well known.